These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 3587405)

  • 1. [Antiparkinson agents].
    Jansen EN; Meerwaldt JD; de Jong GJ
    Ned Tijdschr Geneeskd; 1987 May; 131(18):778-9. PubMed ID: 3587405
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease.
    Wenning GK; Bösch S; Luginger E; Wagner M; Poewe W
    Adv Neurol; 1999; 80():545-8. PubMed ID: 10410769
    [No Abstract]   [Full Text] [Related]  

  • 3. [Preliminary clinical studies on the antiparkinson effects of 17-monochloroacetylajmaline].
    Errichiello G; Maglione S
    Minerva Med; 1974 May; 65(41):2357-9. PubMed ID: 4602984
    [No Abstract]   [Full Text] [Related]  

  • 4. [A drug holiday in the treatment of Parkinson's disease].
    van Manen J
    Ned Tijdschr Geneeskd; 1986 May; 130(20):899-902. PubMed ID: 3724863
    [No Abstract]   [Full Text] [Related]  

  • 5. Piribedil in Parkinsonism.
    Cane DB
    Adv Neurol; 1974; 5():325. PubMed ID: 4613159
    [No Abstract]   [Full Text] [Related]  

  • 6. [Drug treatment of Parkinson's disease].
    Jansen EN
    Ned Tijdschr Geneeskd; 1986 May; 130(20):897-9. PubMed ID: 3724862
    [No Abstract]   [Full Text] [Related]  

  • 7. [Revision of the treatment strategy in Parkinson disease].
    Staal-Schreinemachers AL; Wesseling H; Lakke JP
    Ned Tijdschr Geneeskd; 1986 May; 130(20):914-8. PubMed ID: 3724865
    [No Abstract]   [Full Text] [Related]  

  • 8. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2007 Oct; 5(62):89-94. PubMed ID: 17873854
    [No Abstract]   [Full Text] [Related]  

  • 9. [Current medical treatment of Parkinsonian syndromes].
    Cincă I; Bulandra R; Serbănesco A; Ninosu N
    Rev Roum Neurol; 1973; 10(4):257-85. PubMed ID: 4767886
    [No Abstract]   [Full Text] [Related]  

  • 10. MAO-B inhibitor know-how: back to the pharm.
    Lewitt PA
    Neurology; 2009 Apr; 72(15):1352-7. PubMed ID: 19365057
    [No Abstract]   [Full Text] [Related]  

  • 11. Parcopa: a rapidly dissolving formulation of carbidopa/levodopa.
    Med Lett Drugs Ther; 2005 Jan; 47(1201):12. PubMed ID: 15706700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. It's all in the timing.
    Sadler C
    Nurs Stand; 2007 Feb 21-27; 21(24):20-1. PubMed ID: 17345903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Between Scylla and Charybdis: drug-induced psychosis in patients with Parkinson disease].
    Kuiper MA; Zwaan WA; Wolters EC
    Ned Tijdschr Geneeskd; 1994 Jul; 138(27):1353-7. PubMed ID: 8035892
    [No Abstract]   [Full Text] [Related]  

  • 14. Proceedings: Effects of piribedil (ET 495)--a dopaminergic receptor stimulating agent in Parkinson's disease.
    Lieberman A; Le Brun Y; Zolfaghari M
    Psychopharmacol Bull; 1974 Jul; 10(3):42-3. PubMed ID: 4419369
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term 24-hour duodenal infusion of levodopa: outcome and dose requirements.
    Nutt JG
    Neurology; 2006 May; 66(10):1611-2; author reply 1611-2. PubMed ID: 16717244
    [No Abstract]   [Full Text] [Related]  

  • 16. What to do when Sinemet fails: Part one.
    Klawans HL
    Clin Neuropharmacol; 1984; 7(2):121-33. PubMed ID: 6733692
    [No Abstract]   [Full Text] [Related]  

  • 17. Placebo response in Parkinson trials using patient diaries: sites do matter.
    Ondo WG
    Clin Neuropharmacol; 2007; 30(5):301-4. PubMed ID: 17909309
    [No Abstract]   [Full Text] [Related]  

  • 18. Central atropine-like toxicity in combined psychotropic drug administration.
    el-Yousef MK; Davis JM; Janowsky DS; Fann WE
    J Tenn Med Assoc; 1972 Aug; 65(8):719. PubMed ID: 4152620
    [No Abstract]   [Full Text] [Related]  

  • 19. Future delivery systems for apomorphine in patients with Parkinson's disease.
    van Laar T; Van der Geest R; Danhof M
    Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
    [No Abstract]   [Full Text] [Related]  

  • 20. [Parkinson disease therapy: how great is the progress? Possibilities, limitations and future prospects?].
    Schulz-Hanke I
    Dtsch Med Wochenschr; 2003 Dec; 128(51-52):2689-90. PubMed ID: 14725284
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.